Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms

Inclusion Criteria: * Subjects were enrolled voluntarily and understood the contents of this clinical trial. * Male or female Parkinson disease (PD) patients between 50 and 80 years * Subjects who had not received prokinetics (itopride, mosapride, Corydalis tuber, levosulpiride, domperidone, etc.) at least 2 months prior to baseline visit * Subjects complained at least one symptom of the following that suggests abnormal bowel functions: anorexia, nausea, abdominal distension, dyspepsia, early satiety, dysphagia, foreign body sensation associated with a meal, symptoms of gastroesophageal reflux, constipation, and defecation problem. Exclusion Criteria: * History of a gastrointestinal operation * Subjects with active gastrointestinal diseases under treatment of gastroenterology within 1 month * Existence of clinically significant cognitive decline or K-Minimental Status Exam score 20 or less * Subjects had depression or other psychiatric disorders treated with medications such as antidepressants or antipsychotics; mood tranquilizers, benzodiazepines, and sleep pills were permitted with fixed dose during a period of the clinical trial * Subjects with severe active comorbidities which could interfere the quality of life of the patient * Subjects with medical conditions which make difficult to be enrolled to the trial judged by clinicians * Subjects with hypersensitivity or adverse event related to DA-9701 (Motilitone) * Prior participation to other clinical trials within 3 months